Tirofiban (Aggrastat®) Protects Platelets and Decreases Platelet-Granulocyte Binding in an Extracorporeal Circulation Model[1]

Abstract

Objectives: Extracorporeal circulation (ECC) induces platelet activation and inflammation with potentially life-threatening organ dysfunction. Short-acting GP IIb/IIIa inhibitors like tirofiban and eptifibatide protect platelets during ECC without increasing bleeding complications and may reduce inflammation. This study investigates anti-thrombotic and anti-inflammatory effects of different platelet inhibitors. Methods: Control (untreated) and treated (using either 150 ng/mL tirofiban, 2.5 µg/mL eptifibatide, 0.7 µg/mL milrinone, 15 µg/mL dipyridamol, or 300 KIU/mL aprotinin) heparinized blood of healthy volunteers (n = 6) was recirculated in a well-established ECC model (Chandler loop). Percentage of platelet aggregates, P-selectin-expressing (activated) platelets, CD15-positive aggregates (indicating proinflammatory platelet-granulocyte binding), and platelet counts were determined before (baseline) and after 30 minutes recirculation in unstimulated and ADP-stimulated samples using flow cytometry. Statistical analysis was performed using multifactor ANOVA after transforming the data (logarithms for counts and log odds for percentages). Least square means were backtransformed to obtain appropriate means and their 95 % confidence intervals. Multiple post-hoc comparisons were performed by Tukey's HSD test with a global alpha of 5 %. Results: Significant inhibition was observed for: 1) ECC-induced platelet aggregation by tirofiban (unstimulated: 2.2-fold/stimulated: 2.46-fold), eptifibatide (unstimulated: 1.96-fold/stimulated: 2.65-fold), and milrinone (unstimulated: 1.87-fold/stimulated: 1.37-fold); 2) ECC-induced P-selectin expression by tirofiban (unstimulated: 3.95-fold/stimulated: 2.54-fold), and eptifibatide (unstimulated: 5.87-fold/stimulated: 3.28-fold); 3) ECC-induced platelet loss by tirofiban (1.27-fold), and eptifibatide (1.25-fold); 4) ECC-induced platelet-granulocyte binding by tirofiban (unstimulated: 2.25-fold/stimulated: 1.59-fold), but not by eptifibatide. Conclusions: Amongst the investigated drugs only GP IIb/IIIa inhibitors decreased activation, aggregation, and loss of platelets during ECC but acted differently on platelet-granulocyte interaction. A short-acting GP IIb/IIIa inhibitor with the potential to inhibit platelet activation and platelet-leukocyte interaction should be considered both for platelet protection and inhibition of platelet-mediated inflammation during ECC.

Platelets - inflammation - extracorporeal circulation - GP IIb/IIIa inhibition

References

• 1 Rinder C S, Bonan J L, Rinder H M, Mathew J, Hines R, Smith B R. Cardiopulmonary bypass induces leukocyte-platelet adhesion.  Blood. 1992;  79 1201-1205
• 2 Weerasinghe A, Taylor K M. The platelet in cardiopulmonary bypass.  Ann Thorac Surg. 1998;  66 2145-2152
• 3 Doré M. Platelet-leukocyte interactions.  Am Heart J. 1998;  135 (5 Pt 2 Suppl) S146-151
• 4 Yeo E L, Sheppard J A, Feuerstein I A. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model).  Blood. 1994;  83 2498-2507
• 5 Topol E J, Byzova T V, Plow E F. Platelet GPIIb-IIIa blockers.  Lancet. 1999;  353 227-231
• 6 Bizzarri F, Scolletta S, Tucci E. et al . Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.  J Thorac Cardiovasc Surg. 2001;  122 1181-1185
• 7 Dyke C M, Bhatia D, Lorenz T J. et al . Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy.  Ann Thorac Surg. 2000;  70 866-871 871-872 (discussion)
• 8 Genoni M, Zeller D, Bertel O, Maloigne M, Turina M. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.  J Thorac Cardiovasc Surg. 2001;  122 630-632
• 9 Straub A, Wendel H P, Azevedo R, Ziemer G. The GP IIb/IIIa inhibitor abciximab (ReoPro®) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.  Eur J Cardiothorac Surg. 2005;  27 617-621
• 10 Koster A, Chew D P, Kuebler W. et al . Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass.  Am J Cardiol. 2003;  91 346-347
• 11 Schror K, Weber A A. Comparative pharmacology of GP IIb/IIIa antagonists.  J Thromb Thrombolysis. 2003;  15 71-80
• 12 Gretler D D. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.  Clin Ther. 2003;  25 2564-2574
• 13 Schneider D J, Herrmann H C, Lakkis N. et al . Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.  Am J Cardiol. 2003;  91 334-336
• 14 Anfossi G, Massucco P, Piretto V. et al . Interplay between milrinone and adenosine in the inhibition of human platelet response.  Gen Pharmacol. 1996;  27 1149-1154
• 15 Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.  Thromb Haemost. 1986;  55 12-18
• 16 Royston D, Cardigan R, Gippner-Steppert C, Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen?.  Anesth Analg. 2001;  92 830-836
• 17 Wendel H P, Hauser N, Briquet F, Ziemer G. Hemocompatibility of medical connectors with biopassive or bioactive surface coatings.  J Biomater Appl. 2002;  17 5-17
• 18 Straub A, Azevedo R, Beierlein W, Wendel H, Dietz K, Ziemer G. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.  Thromb Haemost. 2005;  94 115-122
• 19 Kondo N, Wakayama F, Suzuki Y, Fukui K, Takaya S, Fukuda I. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.  Thromb Res. 2004;  113 303-310
• 20 Hiramatsu Y, Gikakis N, Anderson 3rd H L. et al . Tirofiban provides “platelet anesthesia” during cardiopulmonary bypass in baboons.  J Thorac Cardiovasc Surg. 1997;  113 182-193
• 21 Suzuki Y, Hillyer P, Miyamoto S. et al . Integrilin prevents prolonged bleeding times after cardiopulmonary bypass.  Ann Thorac Surg. 1998;  66 373-381
• 22 Levy J H, Bailey J M, Deeb G M. Intravenous milrinone in cardiac surgery.  Ann Thorac Surg. 2002;  73 325-330
• 23 Schmid C, Wilhelm M, Rothenburger M. et al . Effect of high dose platelet inhibitor treatment on thromboembolism in Novacor patients.  Eur J Cardiothorac Surg. 2000;  17 331-335
• 24 Landis R C, Haskard D O, Taylor K M. New antiinflammatory and platelet-preserving effects of aprotinin.  Ann Thorac Surg. 2001;  72 S1808-1813
• 25 Miller B E, Levy J H. The inflammatory response to cardiopulmonary bypass.  J Cardiothorac Vasc Anesth. 1997;  11 355-366
• 26 McEver R P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation.  Thromb Haemost. 2001;  86 746-756
• 27 Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Losche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.  Platelets. 2002;  13 401-406

1 This work has been presented at the 34th Annual Meeting of the German Society for Thoracic and Cardiavascular Surgery (Hamburg, February 15, 2005, session no. 49). The work was supported by a grant of the Medical Faculty of the University of Tübingen (fortüne-program; project-no.: 1164-0-0).